Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates

Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates

This annual webinar is a collaboration between CLSI, Society of Infectious Disease Pharamcists (SIDP), and the American College of Clinical Pharmists (ACCP). It will provide updates on the latest breakpoint recommendations from CLSI from M100 | Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition, and offers practical strategies on incorporating those changes into clinical practice. Speakers will address the importance of partnerships between pharmacists and laboratory professionals on effective implementation of updates to enhance clinical practice. Audience polling will be included throughout, with an opportunity for Q&A at the end.

CLSI members can register for free by signing into their CLSI account. Society of Infectious Disease Pharamcists SIDP and ACCP ID PRN members, please register on SIDP's website

Live Date: Wednesday, August 7, 2024
1:00 PM – 2:30 PM ET / 12:00 PM – 1:30 PM CT

Earn 1.5 P.A.C.E.®️ credits. 

Target Audience:
This activity was planned to meet the educational needs of Pharmacists and Laboratory Professionals.

Learning Objectives:

·       Summarize highlights from the M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition standards for antimicrobial susceptibility testing and reporting

·       Examine nuances that may be encountered when performing antimicrobial susceptibility testing (AST) for carbapenem-resistant bacteria.

·       Evaluate species-specific guidance for AST of Staphylococcus sp. and ceftriaxone dosing guidance for methicillin-susceptible Staphylococcus aureus

·       Discuss the revised breakpoints, reporting, and treatment recommendations for Stenotrophomonas maltophilia


Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.

Virginia M. Pierce, MD, FIDSA

Clinical Associate Professor of Pathology and Pediatrics (Pediatric Infectious Diseases)

University of Michigan Medical School

Dr. Pierce (faculty) has no financial relationships with an ineligible company to disclose.

Navaneeth Narayanan, PharmD, MPH, BCIDP

Clinical Associate Professor

Rutgers University

Dr. Narayanan (faculty): Research funding from Merck and Shionogi; Consultant, Advisor, Speaker

Key:

Complete
Failed
Available
Locked
Breaking Bad Bacteria On-Demand Recording
Overview of Major Updates in CLSI M100
Open to view video.  |  4 minutes
Open to view video.  |  4 minutes
Carbapenem Resistance: Testing and Reporting
Open to view video.  |  10 minutes
Open to view video.  |  10 minutes
Performing AST for Carbapenem-Resistant Enterobacterales
Open to view video.  |  36 minutes
Open to view video.  |  36 minutes
Staphylococcus spp.
Open to view video.  |  15 minutes
Open to view video.  |  15 minutes
Stenotrophomonas Maltophilia
Open to view video.  |  13 minutes
Open to view video.  |  13 minutes
Panel Discussion
Open to view video.  |  4 minutes
Open to view video.  |  4 minutes
P.A.C.E. Credits and Survey
Evaluation
12 Questions
P.A.C.E. Credit and Certificate
1.50 P.A.C.E. credits  |  Certificate available
1.50 P.A.C.E. credits  |  Certificate available